Evidence map›Paper›PMID 28959615›Full record

ArticleToxicology reports2016

Effect of taurine on chronic and acute liver injury: Focus on blood and brain ammonia.

Reza Heidari, Akram Jamshidzadeh, Hossein Niknahad, Elnaz Mardani, Mohammad Mehdi Ommati, Negar Azarpira, Forouzan Khodaei, Azita Zarei, Maryam Ayarzadeh, Somayeh Mousavi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Toxicology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 109 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. 2021 ISHEN guidelines on animal models of hepatic encephalopathy.Liver international : official journal of the International Association for the Study of the Liver · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Reza HeidariPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Akram JamshidzadehPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossein NiknahadPharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Elnaz MardaniDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Mehdi OmmatiDepartment of Animal Science, College of Agriculture, Shiraz University, Shiraz, Iran.
Negar AzarpiraTransplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Forouzan KhodaeiDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Azita ZareiDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam AyarzadehDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Somayeh MousaviDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Narges AbdoliFood and Drug Organization, Ministry of Health, Tehran, Iran.
Babak Shirazi YeganehDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Arastoo SaeediDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Asma NajibiDepartment of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Shiraz University of Medical Sciences · IRIran Nanohealth Committee Food and Drug Organization · IRShiraz University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperammonemia is associated with chronic and acute liver injury. There is no promising therapeutic agent against ammonia-induced complications. Hence, finding therapeutic molecules with safe profile of administration has clinical value. The present study was conducted to evaluate the role of taurine (TA) administration on plasma and brain ammonia and its consequent events in different models of chronic and acute liver injury and hyperammonemia. Bile duct ligated (BDL) rats were used as a model of chronic liver injury. Thioacetamide and acetaminophen-induced acute liver failure were used as acute liver injury models. A high level of ammonia was detected in blood and brain of experimental groups. An increase in brain ammonia level coincided with a decreased total locomotor activity of animals and significant changes in the biochemistry of blood and also liver tissue. TA administration (500 and 1000 mg/kg, i.p), effectively alleviated liver injury and its consequent events including rise in plasma and brain ammonia and brain edema. The data suggested that TA is not only a useful and safe agent to preserve liver function, but also prevented hyperammonemia as a deleterious consequence of acute and chronic liver injury.

Indexed as

4-Nitrophenol (PubChemCID: 980)5, 5′ Dithiobis (2-nitrobenzoic acid) (PubChem CID: 6254)Acetaminophen (PubChem CID: 1983)Amino acidAmmoniaBrain edemaHepatic encephalopathyHepatic injuryHepatoprotectiveTaurine (PubChem CID: 1123)Thioacetamide (PubChem CID: 2723949)Thiobarbituric acid (PubChem CID: 2723628)

Identifiers

PMID28959615
PMCPMC5615919
OpenAlexW2335920413

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.